Skip to main content
Michael Choi, MD, Gastroenterology, Worcester, MA

Michael Yoon-Suk Choi MD


Co-Founder, Mediar Therapeutics

Join to View Full Profile
  • 119 Belmont StWorcester, MA 01605

  • Phone+1 508-334-2846

  • Fax+1 508-856-3981

Dr. Choi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Dana-Farber Cancer Institute
    Dana-Farber Cancer InstitutePost-Doctoral Fellowship, 2003 - 2008
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalFellowship, Gastroenterology, 2000 - 2005
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1999 - Present
  • MA State Medical License
    MA State Medical License 2003 - 2026
  • NH State Medical License
    NH State Medical License 2024 - 2026
  • ME State Medical License
    ME State Medical License 2010 - 2025
  • Gastroenterology
    American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Publications & Presentations

PubMed

Lectures

  • Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Enzyme Treatment Reduces Alcohol-Induced Liver Damage in Mouse Models
    Enzyme Treatment Reduces Alcohol-Induced Liver Damage in Mouse ModelsApril 25th, 2017

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: